Epiodyne was founded to develop breakthrough small molecule medicines based upon novel insights into GPCR receptor pharmacology that were uncovered by leading researchers at UCSF, Stanford and Duke. Together with our founders and with the highly experienced medicinal chemistry team at R2M Pharma (https://www.linkedin.com/company/r2m-pharma/), we are using quantitative pharmacological and behavioral techniques to translate our insights into novel medicines for patients with opioid use disorder (OUD). We are backed by a syndicate of experienced biotech VCs and located in the Bay Area.
-------- At this time we are NOT hiring for data entry roles ------
Company Details
- Employees
- 3
- Founded
- 2016
- Address
- 953 Indiana St, San Francisco,california,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- epiodyne.com
- Keywords
- Biotechnology, Opiate use disorder, Pharmaceuticals and medicinal chemistry, behavioral pharmacology, GPCR.
- HQ
- San Francisco, California
Epiodyne Questions
Epiodyne's website is epiodyne.com
Epiodyne's LinkedIn profile is https://www.linkedin.com/company/epiodyne
Epiodyne has
3 employees.
View email and phone details for 3
employees at Epiodyne.
Epiodyne's industry is
Biotechnology Research
Epiodyne's top competitors are
Arcus Biosciences,
Encoded Therapeutics Inc.,
Stingray Therapeutics,
Xylo Bio,
Mission Biocapital,
Aditum Bio,
Particle Health,
R2m Pharma, Inc.,
Delfi Diagnostics,
Human Strategy.
Epiodyne's categories are Biotechnology Research
Epiodyne's founding year is 2016
